NASDAQ$OBIO
Orchestra Biomed Holdings In · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Orchestra BioMed reported Q3 2025, revenue of $2.1M, net loss of $15M.
For Q3 2025, Orchestra BioMed reported revenue of $2.1M, a net loss of $15M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Revenue $2.1M.
- Net loss $15M.
- Orchestra BioMed MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Orchestra Biomed · Revenue · Quarterly
$861K
Revenue by segment
Orchestra Biomed · $2.64M total across 2 segments · Q4 2024
- Partnership revenue$2.01M-4.8%76.0%
- Product revenue$633K-3.2%24.0%
Forward guidance
Clinical-stage or royalty biotech outlook centers on trial readouts, partnerships, and cash runway.
Tailwinds
- Pipeline milestones and collaboration optionality.
- Cash and marketable securities fund operations.
Headwinds
- Trial failure or delay risk.
- Dilution from future financings.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
+4.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+5.7%
Avg return
30 days after
63%
12 / 19 earnings
Positive
+30.5%
Q4 2022
Best reaction
-6.0%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -4.9% | +4.1% | |
| Q4 2025 | +4.7% | +4.9% | -2.0% | |
| Q3 2025 | +4.6% | +12.4% | +9.1% | |
| Q2 2025 | -2.6% | +1.8% | +4.0% | |
| Q1 2025 | +0.3% | -5.9% | +16.6% | |
| Q4 2024 | -6.0% | -4.4% | -11.1% | |
| Q3 2024 | -1.0% | -4.7% | -12.9% | |
| Q2 2024 | -3.7% | +3.7% | -8.1% | |
| Q1 2024 | +10.4% | +10.6% | +68.6% | |
| Q4 2023 | +0.2% | -5.9% | -16.5% | |
| Q3 2023 | +29.6% | +28.8% | +58.3% | |
| Q2 2023 | +5.3% | -0.5% | +9.2% | |
| Q1 2023 | +2.5% | +15.3% | -16.8% | |
| Q4 2022 | +30.5% | -12.1% | -1.6% | |
| Q3 2022 | +0.3% | -0.4% | +0.1% | |
| Q2 2022 | +0.0% | +0.1% | +0.2% | |
| Q4 2021 | +0.0% | +0.2% | +0.4% | |
| Q1 2022 | +0.0% | +0.2% | +0.4% | |
| Q1 2021 | +3.7% | +1.8% | +6.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro